DrugCite
Search

MAVIK

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Mavik Adverse Events Reported to the FDA Over Time

How are Mavik adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Mavik, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Mavik is flagged as the suspect drug causing the adverse event.

Most Common Mavik Adverse Events Reported to the FDA

What are the most common Mavik adverse events reported to the FDA?

Myocardial Infarction
55 (3.73%)
Atrial Fibrillation
30 (2.04%)
Fall
28 (1.9%)
Death
27 (1.83%)
Cardiac Failure Congestive
19 (1.29%)
Dyspnoea
19 (1.29%)
Infarction
18 (1.22%)
Cerebrovascular Accident
16 (1.09%)
Chest Pain
16 (1.09%)
Cough
16 (1.09%)
Cardiac Failure
15 (1.02%)
Show More Show More
Asthenia
14 (.95%)
Angina Pectoris
13 (.88%)
Blood Pressure Decreased
13 (.88%)
Dizziness
13 (.88%)
Hypotension
13 (.88%)
Pneumonia
13 (.88%)
Transient Ischaemic Attack
13 (.88%)
Angioedema
12 (.81%)
Carotid Artery Stenosis
12 (.81%)
Drug Dose Omission
12 (.81%)
Malaise
12 (.81%)
Pericardial Drainage
12 (.81%)
Syncope
12 (.81%)
Coronary Artery Disease
11 (.75%)
Hip Fracture
11 (.75%)
Lung Neoplasm Malignant
11 (.75%)
Oedema Peripheral
11 (.75%)
Weight Decreased
11 (.75%)
Complications Of Transplanted Liver
10 (.68%)
Drug Ineffective
10 (.68%)
Femur Fracture
10 (.68%)
Hypothyroidism
10 (.68%)
Pancreatitis Acute
10 (.68%)
Pulmonary Oedema
10 (.68%)
Sepsis
10 (.68%)
Blood Pressure Increased
9 (.61%)
Breast Cancer
9 (.61%)
Gastric Cancer
9 (.61%)
Hospitalisation
9 (.61%)
Metastatic Neoplasm
9 (.61%)
Mobility Decreased
9 (.61%)
Post Procedural Complication
9 (.61%)
Urticaria
9 (.61%)
Abdominal Pain
8 (.54%)
Acute Coronary Syndrome
8 (.54%)
Blood Potassium Decreased
8 (.54%)
Blood Pressure Inadequately Control...
8 (.54%)
Cardiac Arrest
8 (.54%)
Coronary Artery Thrombosis
8 (.54%)
Renal Failure Acute
8 (.54%)
Urinary Tract Infection
8 (.54%)
Cardiac Disorder
7 (.47%)
Coronary Artery Occlusion
7 (.47%)
Dysphagia
7 (.47%)
Haematoma
7 (.47%)
Multiple Myeloma
7 (.47%)
Neoplasm Malignant
7 (.47%)
Orthostatic Hypotension
7 (.47%)
Pain In Extremity
7 (.47%)
Road Traffic Accident
7 (.47%)
Cardiovascular Disorder
6 (.41%)
Dementia
6 (.41%)
Haemorrhage
6 (.41%)
Headache
6 (.41%)
Hypertension
6 (.41%)
Multiple Sclerosis
6 (.41%)
Osteoarthritis
6 (.41%)
Palpitations
6 (.41%)
Pneumothorax
6 (.41%)
Renal Failure
6 (.41%)
Respiratory Failure
6 (.41%)
Right Ventricular Dysfunction
6 (.41%)
Throat Irritation
6 (.41%)
Ventricular Hypokinesia
6 (.41%)
Calculus Bladder
5 (.34%)
Cardiac Tamponade
5 (.34%)
Cheilitis
5 (.34%)
Chest Discomfort
5 (.34%)
Chronic Obstructive Pulmonary Disea...
5 (.34%)
Colon Cancer
5 (.34%)
Convulsion
5 (.34%)
Diabetes Mellitus
5 (.34%)
Fracture Displacement
5 (.34%)
Hiatus Hernia
5 (.34%)
Intestinal Obstruction
5 (.34%)
Loss Of Consciousness
5 (.34%)
Lung Squamous Cell Carcinoma Stage ...
5 (.34%)
Mineral Deficiency
5 (.34%)
Mitral Valve Disease
5 (.34%)
Visual Acuity Reduced
5 (.34%)
Aphasia
4 (.27%)
Arterial Occlusive Disease
4 (.27%)
Arteriosclerosis Coronary Artery
4 (.27%)
Bile Duct Stone
4 (.27%)
Cholangitis Acute
4 (.27%)
Coronary Artery Stenosis
4 (.27%)
Dysarthria
4 (.27%)
Fatigue
4 (.27%)
Glomerulonephritis Membranous
4 (.27%)
Hysterectomy
4 (.27%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Mavik, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Mavik is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Mavik

What are the most common Mavik adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Mavik, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Mavik is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Mavik According to Those Reporting Adverse Events

Why are people taking Mavik, according to those reporting adverse events to the FDA?

Hypertension
261
Essential Hypertension
188
Drug Use For Unknown Indication
144
Product Used For Unknown Indication
33
Blood Pressure
21
Blood Pressure Increased
11
Show More Show More
Myocardial Infarction
9
Steroid Therapy
6
Cardiac Failure Congestive
5
Acute Myocardial Infarction
4
Coronary Artery Disease
4
Blood Pressure Abnormal
3
Blood Pressure Management
2
Cardiac Disorder
2
Cardiomyopathy
2
Type 2 Diabetes Mellitus
2
Angina Pectoris
1
Microalbuminuria
1
Blood Pressure Inadequately Control...
1
Cardiac Failure
1
Diabetes Mellitus
1
Blood Cholesterol Increased
1
Palpitations
1

Drug Labels

LabelLabelerEffective
MavikPhysicians Total Care, Inc.14-FEB-12
MavikAbbott Laboratories27-SEP-12

Mavik Case Reports

What Mavik safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Mavik. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Mavik.